Strasbourg

• Study evaluating two treatment strategies for rectal cancer in patients ≥75 years old Pending
  2025-521619-37-00 5 Patients ≥75 years old with cT3/T4 rectal adenocarcinoma eligible to r
• An Open-Label Study of ML-007C-MA in Adults with Alzheimer’s Disease Psychosis Pending
  2025-521757-16-00 4 Hallucinations and Delusions Associated with Alzheimer’s Disease Psych
• KARMA - INtenSive care TreAtmeNT with adjuvant KetAmine and Recovery after Mechanical ventilAtion: a multicenter doubleblind randomized cont … Pending
  2025-523149-80-00 10 Adult patients admitted to the ICU and receiving unplanned invasive me
• Evaluation of MTX-474 in Participants with Diffuse Cutaneous Systemic Sclerosis (dcSSc) Pending
  2025-523288-39-00 4 Diffuse Cutaneous Systemic Sclerosis (dcSSc)
• Skipping Hormone Therapy in Low-Risk Early Breast Cancer Pending
  2025-523683-20-00 4 Postmenopausal patients with small (pT1a-b pN0) hormone receptor posit
• ADRESS : Efficacy of the Alpha 2 agonist dexmedetomidine for sympathetic Deactivation in REfractory Septic Shock: a randomized, controlled t … Pending
  2025-524122-18-00 5 Septic shock
• TAILORswitch (PADA-2): rising ctDNA to tailor endocrine therapy switch in patients with ER+/HER2- metastatic breast cancer. Pending
  2025-524213-84-00 5 Patients with advanced or metastatic ER+ HER2- breast cancer
• REGENOVAR: A Phase I/II Study of Ubamatamab Plus Carboplatin, Paclitaxel, and Bevacizumab as Salvage Therapy in Ovarian Cancer with Poor Res … Pending
  2025-524232-20-00 7 Patients with poor prognostic ovarian cancers based on the tumor prima
• Achieve - ACetazolamide in patients with Heart failure, to decrease weight and relIEVE symptoms Pending
  2025-524344-35-00 5 Heart failure
• A study to find out if enfortumab vedotin given with pembrolizumab helps people with muscle-invasive bladder cancer keep their bladder. Pending
  2025-524488-18-00 4 Muscle-invasive Bladder Cancer
• EPISSOC : Randomized controlled trial comparing an Early Pleural Irrigation strategy with Saline to the Standard of Care for the management … Pending
  2025-524697-42-00 5 Pleural infections
• A Phase 1b-2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of LRK-4189 Alone and … Pending
  2026-525629-20-00 9 Solid tumors
• Open-label Extension of KarXT + KarX-EC for Agitation in Alzheimer’s Disease Recruiting
  2024-519994-20-00 5 2026-06-01 Agitation Associated with Alzheimer’s Disease
• ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP) Recruiting
  2025-521711-39-00 5 2026-05-17 Lewy body Dementia psychosis (LBDP)
• Phase 3 study comparing ivonescimab alone or ivonescimab with ligufalimab versus pembrolizumab for the first-line treatment of recurrent and … Recruiting
  2025-522996-27-00 5 2026-05-05 recurrent and/or metastatic squamous cell carcinoma of the head and ne
• Evaluating a Personalized Treatment Strategy for Young Women with Early Breast Cancer Recruiting
  2024-519655-28-00 5 2026-04-23 Premenopausal patients with high-risk HR-positive/HER2-negative breast
• ROSETTA Breast-01: The effects and safety of pumitamig in patients with triple-negative breast cancer Recruiting
  2025-521884-12-00 5 2026-03-19 First line triple-negative breast cancer (TNBC)
• An Efficacy and Safety Study of Trontinemab in Participants With Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia Due to AD) Recruiting
  2024-518006-40-00 5 2025-11-13 Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia Due to AD)
• A phase 2/3, multi-center, study of L-Annamycin in combination with cytarabine vs. placebo in combination with cytarabine as second line the … Recruiting
  2024-518359-47-00 10 2025-06-17 Acute Myeloid Leukemia
• A Phase 1/2a, First-in-human Study to Evaluate BMS-986470 in Healthy Volunteers and Participants with Sickle Cell Disease Recruiting
  2023-510283-12-00 7 2025-06-12 Sickle Cell Disease
• Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast C … Recruiting
  2024-515445-42-00 5 2025-03-24 Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast
• Dose dense re-challenge of high dose methotrexate (hd-mtx) with glucarpidase (cpg2) for relapsed primary cns lymphoma (pcnsl): A phase 1 tri … Recruiting
  2024-511900-17-00 3 2025-02-14 Oncology: RELAPSED PRIMARY CNS LYMPHOMA
• TAR-0520 gel in EGFR inhibitor-induced folliculitis Recruiting
  2024-516339-28-00 4 2025-02-10 EGFR inhibitor-induced folliculitis
• A randomized phase 3, double-blind, placebo-controlled study of elacestrant plus everolimus versus elacestrant in patients with estrogen rec … Recruiting
  2024-512926-27-00 5 2024-12-12 patients with estrogen receptor-positive/human epidermal growth factor

Showing 25–48 of 377 trials